Abstract
Cellular therapy products are highly regulated in the United States both at the state and federal levels. The Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) are the main governing bodies that provide federal oversight. State health departments may also have local regulations for processing laboratories. Individuals and institutions involved in cellular therapy processing must be familiar with the requirements of these agencies. Cellular therapy processing laboratories may also be accredited by organizations such as the Foundation for the Accreditation of Cellular Therapy (FACT), Joint Accreditation Committee-ISCT and EBMT (JACIE), or American Association of Blood Banks (AABB). While regulations have the force of law, accreditation standards are not legally binding. Accreditation allows an organization or institution to be officially recognized as being highly qualified to perform cellular therapy activities and to have a high quality of operations. The federal government has granted deemed status to certain accreditation organizations that have standards and a survey process that meets or exceeds Medicare and Medicaid requirements. Laboratories that achieve accreditation through an organization’s “deemed status” survey are determined to meet or exceed federal requirements. In this chapter we discuss the regulations and accreditation steps of cellular processing laboratories by various organizations.
References
AABB, America’s Blood Centers, the American Association of Tissue Banks, the American Red Cross, the American Society for Apheresis, the American Society for Blood and Marrow Transplantation, the College of American Pathologists, the Cord Blood Association, the Foundation for the Accreditation of Cellular Therapy, ICCBBA, the International Society for Cellular Therapy, the Joint Accreditation Committee of ISCT and EBMT, the National Marrow Donor Program, and Netcord (2016) Circular of information for the use of cellular therapy products. AABB, Bethesda, MD
AABB (n.d.-a) Accreditation program overview. http://www.aabb.org/sa/overview/Pages/default.aspx
AABB (n.d.-b) Accreditation program. http://www.aabb.org/sa/overview/Pages/program.aspx
AABB (n.d.-c) Become an AABB accredited facility (or add a new activity). http://www.aabb.org/sa/becomeaccredited/Pages/default.aspx
AABB AsBC, the American, Association of Tissue Banks tARC, the American Society for Apheresis, the, American Society for Blood and Marrow Transplantation tCoAP, the Cord Blood Association tFftAoCT, ICCBBA,, the International Society for Cellular Therapy tJACoI, and EBMT tNMDP, and Netcord (2016) Circular of information for the use of cellular therapy products. AABB, Bethesda, MD
ACHTA (n.d.-a) Documents. http://www.ahcta.org/docs/Mission%20statement%20AHTCA%20FINAL.pdf
ACHTA (n.d.-b) Resources. http://www.ahcta.org/resources.html
CAP (n.d.) Laboratory accreditation program. http://www.cap.org/web/home/lab/accreditation/laboratory-accreditation-program?_afrLoop=402948075743307#!%40%40%3F_afrLoop%3D402948075743307%26_adf.ctrl-state%3Dvy7a0e7fa_4
CDC (n.d.-a) Public health service act Sec 353. https://wwwn.cdc.gov/cliac/pdf/Addenda/cliac0910/Addendum%20C_Yost.pdf
CDC (n.d.-b) Clinical laboratory improvement amendments (CLIA)—test complexities. https://wwwn.cdc.gov/clia/resources/testcomplexities.aspx
CMS (n.d.-a) Clinical laboratory improvement amendments (CLIA). https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html
CMS (n.d.-b) Proficiency testing programs. https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Proficiency_Testing_Providers.html
CMS (n.d.-c) Clinical laboratory improvement amendments (CLIA). How to obtain a CLIA certificate. https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/downloads/howobtaincliacertificate.pdf
CMS (n.d.-d) List of approved accreditation organizations under the clinical laboratory improvement amendments (CLIA). https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/AOList.pdf
CMS (n.d.-e) Approved proficiency testing programs—2017. https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/ptlist.pdf
EBMT (n.d.) About JACIE. https://www.ebmt.org/Contents/Quality-Management/AboutJACIE/Pages/About-JACIE.aspx
FACT (n.d.) Process overview. http://www.factwebsite.org/accreditationprocess/
FDA (n.d.) About FDA guidances. https://www.fda.gov/Drugs/%20GuidanceComplianceRegulatoryInformation/Guidances/default.htm
GPO (n.d.) Code of federal regulations. https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR
JACIE (n.d.-a) First-time application. http://www.jacie.org/applicants/first-time-application
JACIE (n.d.-b) Pre-inspection documents http://www.jacie.org/applicants/pre-inspection-documents
JACIE (n.d.-c) The inspection. http://www.jacie.org/applicants/inspection
JACIE (n.d.-d) Annual report. http://www.jacie.org/applicants/annual-report
JACIE (n.d.-e) Interim audit. http://www.jacie.org/applicants/interim-audit
NMDP (n.d.) NMDP standards. https://bethematch.org/about-us/global-transplant-network/standards/
Rauch CA (2007) Laboratory accreditation and inspection. Clin Lab Med 27(4):845–858
The Joint Commission (n.d.) Facts about the Cooperative Accreditation Initiative https://www.jointcommission.org/facts_about_the_cooperative_accreditation_initiative/
U.S. Food and Drug Administration (n.d.-a) Tissue & tissue products. https://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/default.htm
U.S. Food and Drug Administration (n.d.-b) Minimal manipulation of human cells, tissues, and cellular and tissue-based products: draft guidance. https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm427692.htm
U.S. Food and Drug Administration (n.d.-c) Registration and listing. https://www.fda.gov/forindustry/fdabasicsforindustry/ucm234625.htm
U.S. Food and Drug Administration (n.d.-d) What does FDA inspect? https://www.fda.gov/AboutFDA/Transparency/basics/ucm194888.htm
U.S. Food and Drug Administration (n.d.-e) CLIA—clinical laboratory improvement amendments—currently waived analytes. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/analyteswaived.cfm
U.S. Food and Drug Administration (n.d.-f) CLIA—clinical laboratory improvement amendments search database https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/search.cfm
WMDA (n.d.-a) Who we are. https://www.wmda.info/about-us/who-we-are
WMDA (n.d.-b) WMDA accreditation programme
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Tanhehco, Y.C., Schwartz, J. (2018). Regulations and Accreditation of Processing Laboratories. In: Schwartz, J., Shaz, B. (eds) Best Practices in Processing and Storage for Hematopoietic Cell Transplantation . Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-58949-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-58949-7_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-58948-0
Online ISBN: 978-3-319-58949-7
eBook Packages: MedicineMedicine (R0)